億帆醫藥(002019.SZ):獲得注射用鹽酸表柔比星、注射用阿糖胞苷的藥品註冊證書
格隆匯6月4日丨億帆醫藥(002019.SZ)公佈,公司全資子公司合肥億帆生物製藥有限公司於2025年6月4日收到國家藥品監督管理局核准簽發的注射用鹽酸表柔比星、注射用阿糖胞苷《藥品註冊證書》。
注射用鹽酸表柔比星用於治療惡性淋巴瘤、乳腺癌、肺癌、軟組織肉瘤、食道癌、胃癌、肝癌、胰腺癌、黑色素瘤、結腸直腸癌、卵巢癌、多發性骨髓瘤、白血病。膀胱內給藥有助於淺表性膀胱癌、原位癌的治療和預防其經尿道切除術後的復發。
注射用阿糖胞苷主要適用於成人和兒童急性非淋巴細胞性白血病的誘導緩解和維持治療。它對其他類型的白血病也有治療作用,如:急性淋巴細胞性白血病和慢性髓細胞性白血病(急變期)。本品可單獨或與其他抗腫瘤藥聯合應用;聯合用藥療效更好。如果無維持治療,阿糖胞苷誘導的緩解很短暫。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.